Candida glabrata infection in gastric carcinoma patient mimicking cutaneous histoplasmosis

Dermatology Online Journal

Volumn 14, Issue 2, 2008, Pages

  Gugic, Dijana ^a   Cleary, Timothy ^a   Vincek, Vladimir ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CEFTRIAXONE;

ADULT; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; DERMATOMYCOSIS; HISTOPATHOLOGY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; MALE; PUNCH BIOPSY; SKIN NECROSIS; STOMACH CARCINOMA; BACTEREMIA; CARCINOMA; DIFFERENTIAL DIAGNOSIS; ENTEROBACTER INFECTION; FATALITY; FUNGEMIA; IMMUNE DEFICIENCY; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; MICROBIOLOGY; MIDDLE AGED; MUCOCUTANEOUS CANDIDIASIS; STOMACH TUMOR;

BACTEREMIA; CANDIDA GLABRATA; CANDIDIASIS, CUTANEOUS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FUNGEMIA; HISTOPLASMOSIS; HUMANS; IMMUNOCOMPROMISED HOST; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 41149144087     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs. 2000;9(3):593-605.
2. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA, Pinner RW, Hajjeh RA. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999 Nov;29(5):1164-70.
3. Fidel PJ, Vazquez, J. and Sobel J. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;00:80-96.
4. Beck-Sague, CM, and TR Jarvis. Secular trends in the epidemiology of nosocomial fungal infections in the United States. J Infect Dis. 1993;167:1247-1251,
5. Komishian, SV, AK Uwaydah, and JD Sobel. Fungemia caused by Candida species and Toluropsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989;11:379-390.
6. Merz, WG, JE Karp, D Schron, and R. Saral. Increased incidence of fungemia caused by Candida krusei. J. Clin. Microbiol. 1972;24:581-584.
7. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinczowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24(6):1122-8.
8. Redding SW, Dahiya MC, Kirkpatrick WR, Coco BJ, Patterson TF, Fothergill AW, Rinaldi MG, Thomas CR Jr. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radio Endod. 2004;97(1):47-52.
9. Torres HA, Kontoyiannis DP, Rolston KV. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. Support Care Cancer. 2004 Jul;12(7):511-6.
10. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999 May;28(5):1071-9.
11. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995 Jan;20(1):115-25.
12. Safdar A, Armstrong D, Cross EW, Perlin DS. Prospective epidemiologic analysis of triazole-resistant nosocomial Candida glabrata isolated from patients at a comprehensive cancer center. Int J Infect Dis. 2002 Sep;6(3):198-201.
13. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003 Sep;82 (5):309-21.
14. Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002 Sep;23(9):542-5.
15. Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgaway E, Hachem RY, Kontoyiannis DP, Raad II. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002;112:380-385.
16. De Marie S. New developments in the diagnosis and management of invasive fungal infections. Haematologica. 2000;85:88-93.
17. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005;56(S1):5-11.
18. Safdar A, Chaturvedi V, Koll BS, Larone DH, Perlin DS, Armstrong D. Prospective, multicenter surveillance of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida susceptibility trends study, 1998-1999). Antimicrob Agents Chemother. 2002 Oct;46(10):3268-3272.
19. Fairchild KD, Tomkoria S, Sharp EC, Mena FV. Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Padiatr Infect Dis J. 2002;21(1):39-43.
20. Fuchs J, Mildbrat R, Pecher SA. Lobomycosis (keloidal blastomicosis): Case reports and overview. Cutis. 1990;46:227-234.
21. Messer SA, Jones RN, Fritsche TR. International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY antimicrobial surveillance program (2003). J Clin Microbiol. 2006;44(5):1782-1787.
22. Maize JC, Lynch PJ: Chronic mucocutaneous candidiasis of the adult. Arch Dermatol. 1972;105:96-98.
23. Barnhill RL. Textbook of Dermatopathology, 2nd edition, McGraw-Hill, New York, 2004.